Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma MNCs: The menace of 100% subsidiaries - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 10, 2000

    Pharma MNCs: The menace of 100% subsidiaries

    Over the past one year most MNC pharmaceutical companies seem to have gone through a de–rating in valuations. Most of the stocks are quoting at prices almost 60% below their yearly highs.

    Company 52 week high CMP % decline
    Glaxo 971 430 -55.7%
    Hoechst 1,340 472 -64.8%
    SmithKline 445 151 -66.1%
    Knoll 658 354 -46.2%
    Novartis 1,436 914 -36.4%
    Pfizer 640 561 -12.3%

    While the overall slowdown in pharmaceutical sector and a consequent slowdown in topline growth seems to be the prime reason for the current valuation there is another factor pertaining to MNC companies in general and MNC pharmaceutical companies in particular which seems to have affected the sentiment in these stocks. And that is the presence of 100% subsidiaries of the parent companies operating in India.

    Company 100% subsidiary Comments
    Glaxo No Can use SmithKline's 100% arm after the merger is consummated
    Hoechst No The only MNC pharma co active in introducing new products through the listed co
    SmithKline Yes Crocin, Tums, Eno form part of the 100% sub
    Knoll Yes Outsources most of its mfg; new class of products likely through 100% sub
    Novartis Yes Introduction of nutritional products through the sub
    Pfizer Yes Ostensibly for R & D; lifestyle products likely through the 100% sub.

    Of the top six pharmaceutical MNCs four companies viz. Pfizer, Novartis, Knoll and SmithKline Pharmaceutical have 100% subsidiaries operating in India. While the ostensible reason seems to be that these companies would conduct research in India, the fact is that these are most likely to be used to introduce new products.

    It could also lead to a situation that eventually the listed company is functional only as a trading company. The strategy that could be adopted is  milk existing brands by transferring manufacturing to low-cost third parties and reduce overheads through VRS and the closure of own plants;  transfer profits where feasible through royalties and technical know how fees and  launch drugs through fully-owned subsidiaries.

    To be fair to the management’s of these companies it is far more advantageous for the parent to maintain a 100% subsidiary for the simple reason that while the company earns from the Indian market, it need not share its profits with Indian shareholders. Some large MNC's notably Hoechst and Glaxo are introducing more products through the listed subsidiary and exploring possibilities of tie-ups and alliances to leverage their existing distribution strengths and franchise.

    However, it is for the government to have a clear–cut policy on this matter. While the government has allowed MNC pharma companies to hike their stake in their existing subsidiaries to 74%, it is still allowing the setting up of 100% companies (Pfizer has been one of the most recent examples.)

    What the government needs to do is to make it compulsory for companies to offer 26% of their equity to the Indian public and free up investment norms for pharmaceutical companies rather than give permission for 100% subsidiaries on a case by case (or is it suitcase by suitcase?) basis. Only that could allow Indian investors to participate in the relatively higher profits of top class MNC pharmaceutical companies who introduce their top of the line patented products post 2005.



    Equitymaster requests your view! Post a comment on "Pharma MNCs: The menace of 100% subsidiaries". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)